Ovid Therapeutics Inc (OVID)

Jan 06, 2026

Aug Spikes: Can Ovid Therapeutics Inc 1OT stock sustain breakout momentumEarnings Overview Report & Safe Capital Growth Stock Tips - moha.gov.vn

Jan 06, 2026

Jan 06, 2026

How Ovid Therapeutics Inc. stock reacts to oil prices2026 world cup usa national team qualification goalkeepers low block defense knockout prediction statistical analysis - Улправда

Jan 06, 2026

Jan 06, 2026

Is Ovid Therapeutics Inc. stock positioned well for digital economy2026 world cup usa national team round of 32 defensive leaders low block defense group prediction preview - Улправда

Jan 06, 2026

Jan 06, 2026

2026 world cup fixtures tips: How Ovid Therapeutics Inc. stock performs in weak economy2026 world cup usa national team quarterfinals young talents pressing system tactical prediction guide - Улправда

Jan 06, 2026

Dec 29, 2025

Ovid Therapeutics is a buy, this analyst says - Cantech Letter

Dec 29, 2025

Dec 27, 2025

Wall Street Zen Upgrades Ovid Therapeutics (NASDAQ:OVID) to "Hold" - MarketBeat

Dec 27, 2025

Dec 26, 2025

Ovid Therapeutics (STU:1OT) EV-to-FCF : -2.91 (As of Dec. 26, 2025) - GuruFocus

Dec 26, 2025

Dec 26, 2025

Ovid Therapeutics (STU:1OT) EV-to-OCF : -2.91 (As of Dec. 27, 2025) - GuruFocus

Dec 26, 2025

Dec 26, 2025

Promising Penny Stocks To Watch In December 2025 - simplywall.st

Dec 26, 2025

Dec 24, 2025

FY2025 Earnings Forecast for OVID Issued By Lifesci Capital - MarketBeat

Dec 24, 2025

Dec 22, 2025

LifeSci Capital Initiates Coverage of Ovid Therapeutics (OVID) with Outperform Recommendation - Nasdaq

Dec 22, 2025

Dec 22, 2025

Form 424B3 Ovid Therapeutics Inc. - StreetInsider

Dec 22, 2025

Dec 22, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Dec 22, 2025

Dec 22, 2025

Ovid Therapeutics (OVID) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 22, 2025

Dec 22, 2025

Ovid Therapeutics (NASDAQ:OVID) Earns Outperform Rating from Analysts at Lifesci Capital - MarketBeat

Dec 22, 2025

Dec 22, 2025

Ovid Therapeutics' (OVID) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Dec 22, 2025

Dec 22, 2025

OVID: HC Wainwright Reiterates Buy Rating with $2.00 Price Targe - GuruFocus

Dec 22, 2025

Dec 22, 2025

HC Wainwright & Co. Reiterates Ovid Therapeutics (OVID) Buy Recommendation - Nasdaq

Dec 22, 2025

Dec 21, 2025

Is Ovid Therapeutics Inc. stock undervalued vs historical averagesJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда

Dec 21, 2025

Dec 20, 2025

How Ovid Therapeutics Inc. (1OT) stock stacks up against competitorsWeekly Trade Report & Smart Investment Allocation Insights - Улправда

Dec 20, 2025

Dec 19, 2025

Will Ovid Therapeutics Inc. stock recover faster than peersGold Moves & Real-Time Volume Triggers - DonanımHaber

Dec 19, 2025

Dec 19, 2025

Is Ovid Therapeutics Inc. stock a smart buy before Fed meetingWatch List & Safe Entry Trade Reports - Улправда

Dec 19, 2025

Dec 19, 2025

How Ovid Therapeutics Inc. stock performs in weak economyMarket Rally & Technical Confirmation Trade Alerts - Улправда

Dec 19, 2025

Dec 18, 2025

Takeda’s Zasocitinib Marks Another Win In Late-Stage Pipeline Strategy - Citeline News & Insights

Dec 18, 2025

Dec 18, 2025

Ovid’s KCC2 activator shows promising safety in early trial By Investing.com - Investing.com Nigeria

Dec 18, 2025

Dec 18, 2025

Ovid Therapeutics Advances Oral KCC2 Activators After OV350 Data - TipRanks

Dec 18, 2025

Dec 18, 2025

Ovid Therapeutics announces phase 1 results for Ov350 - marketscreener.com

Dec 18, 2025

Dec 18, 2025

Ovid Therapeutics Inc Reports Phase 1 Results for OV350 - TradingView — Track All Markets

Dec 18, 2025

Dec 18, 2025

Ovid’s KCC2 activator shows promising safety in early trial - Investing.com

Dec 18, 2025

Dec 18, 2025

Ovid Therapeutics Reports Phase 1 Results for the - GlobeNewswire

Dec 18, 2025

Dec 16, 2025

Ovid Therapeutics (NASDAQ:OVID) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Dec 16, 2025

Dec 13, 2025

Aug Big Picture: How analysts rate Ovid Therapeutics Inc stock todayWeekly Loss Report & Technical Confirmation Alerts - moha.gov.vn

Dec 13, 2025

Dec 12, 2025

Janus Henderson Group PLC Acquires Significant Stake in Ovid The - GuruFocus

Dec 12, 2025

Dec 12, 2025

Roth Capital Initiates Coverage on Ovid Therapeutics (NASDAQ:OVID) - MarketBeat

Dec 12, 2025

Dec 11, 2025

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals - Investing.com Canada

Dec 11, 2025

Dec 11, 2025

Ovid Therapeutics shareholders approve increase in authorized shares and related proposals By Investing.com - Investing.com South Africa

Dec 11, 2025

Dec 11, 2025

Ovid Therapeutics Stockholders Approve Key Proposals - TipRanks

Dec 11, 2025

Dec 11, 2025

Roth Capital Initiates Coverage of Ovid Therapeutics (OVID) with Buy Recommendation - Nasdaq

Dec 11, 2025

Dec 11, 2025

Roth/MKM initiates Ovid Therapeutics stock with Buy rating on epilepsy drug - Investing.com Canada

Dec 11, 2025

Dec 11, 2025

OVID: Roth Capital Initiates Coverage with a "Buy" Rating at $3. - GuruFocus

Dec 11, 2025

Dec 11, 2025

Roth Capital Initiates Ovid Therapeutics With Buy Rating, $3 Price Target - marketscreener.com

Dec 11, 2025

Dec 07, 2025

What analysts say about Ovid Therapeutics Inc stockTrading Volume Surges & Capitalize On Fast Trends - earlytimes.in

Dec 07, 2025

Dec 05, 2025

Will Ovid Therapeutics Inc. stock deliver long term returns - Newser

Dec 05, 2025

Dec 05, 2025

Will Ovid Therapeutics Inc. (1OT) stock see valuation expansionEarnings Recap Report & Low Risk High Win Rate Stock Picks - Newser

Dec 05, 2025

Dec 04, 2025

Will Ovid Therapeutics Inc. (1OT) stock gain from lower interest ratesPortfolio Performance Summary & Weekly Market Pulse Alerts - Newser

Dec 04, 2025

Dec 04, 2025

Minerva jumps on phase III funding, leading neuro stocks - BioWorld MedTech

Dec 04, 2025

Dec 04, 2025

Will Ovid Therapeutics Inc. stock gain from strong economyDividend Hike & Precise Entry and Exit Recommendations - Newser

Dec 04, 2025